New Delhi: The Pune-based Serum Institute of India (SII) will start manufacturing the anti-COVID vaccine Sputnik V from September, Russian authorities said on Tuesday. The RDIF (Russian Direct Investment Fund) ...
Pune: India's premier vaccine manufacturer, Serum Institute of India (SII), has sought permission from Drugs Controller General of India (DCGI) to conduct a study trial using US-based Novavax's COVID-19 vaccine. ...
Pune: Serum Institute of India (SII) confirmed that it suffered losses to the tune of Rs 1,000 crore in Thursday’s fire, though the supplies or production of the COVID-19 vaccine ...
Pune: The fire at Serum Institute of India (SII) that killed five workers on Thursday won’t result in any loss of Covishield coronavirus vaccine due to “multiple production buildings”, but ...
Pune: Five persons lost their lives after a fire broke out at an under-construction site in Serum Institute of India’s (SII) Manjari building premises here on Thursday, police said. Nine ...
Pune: The CEO of Serum Institute of India (SII), Adar Poonawalla, on Tuesday said his firm has decided to sell the first 100 million doses of Covishield vaccine at a ...
New Delhi: A day ahead of the scheduled dry run for vaccination in all the states, a government-appointed panel of experts on Friday cleared the Oxford COVID-19 vaccine manufactured by ...
New Delhi: India will require funding of Rs 80,000 crore for distribution of the COVID vaccine for the next one year, said Serum Institute of India, which has partnered with ...
New Delhi: Serum Institute of India (SII) and Bharat Biotech have not been granted emergency use authorisation of their coronavirus vaccine because of inadequate safety and efficacy data. According to ...
New Delhi: The Serum Institute of India (SII) has sought emergency use authorisation of its vaccine candidate Covishield in the country. The Pune-based SII is conducting the India trials of ...
Copyright © 2025 Frontier Media
